Table 3. Predictors of discontinuation by immunomodulatory treatment in early MS and CIS (Univariable Cox Regression).
| Predictor | Level | IM IFNβ-1a | SC IFNβ-1a | IFNβ-1b | GA | ||||||||
| UHR (95% CI) | p | UHR (95% CI) | p | UHR (95% CI) | p | UHR (95% CI) | p | ||||||
| Age at treatment commencement | − | 0.98 (0.97, 1.00) | 0.059 | 0.99 (0.97, 1.00) | 0.086 | 1.00 (0.98, 1.02) | 0.760 | 1.02 (1.00, 1.05) | 0.105 | ||||
| Years between onset of symptoms and treatment start | - | 0.99 (0.84, 1.18) | 0.935 | 0.98 (0.81, 1.18) | 0.848 | 0.93 (0.78, 1.11) | 0.410 | 1.07 (0.84, 1.37) | 0.584 | ||||
| Change in EDSS | - | 1.23 (1.12, 1.36) | <0.001 | 1.26 (1.14, 1.40) | <0.001 | 1.01 (0.87, 1.19) | 0.857 | 1.24 (1.03, 1.50) | 0.021 | ||||
| Sex | Female | 1.45 (1.00, 2.08) | 0.048 | 1.49 (1.07, 2.07) | 0.018 | 1.52 (0.93, 2.47) | 0.094 | 0.94 (0.52, 1.69) | 0.842 | ||||
| Male | 1.00 | 1.00 | 1.00 | 1.00 | |||||||||
| Location | Australia | 2.58 (1.23, 5.43) | 0.013 | 1.42 (0.62, 3.27) | 0.409 | 1.52 (0.77, 3.02) | 0.229 | 2.57 (0.84, 7.92) | 0.099 | ||||
| Canada | 2.40 (1.23, 4.68) | 0.010 | 1.51 (0.70, 3.24) | 0.289 | 0.95 (0.45, 2.02) | 0.901 | 1.54 (0.50, 4.79) | 0.455 | |||||
| Netherlands | 1.05 (0.46, 2.44) | 0.901 | 1.25 (0.57, 2.76) | 0.577 | 0.96 (0.46, 2.00) | 0.908 | 2.92 (0.96, 8.89) | 0.059 | |||||
| Spain | 1.00 | 1.00 | 1.00 | 1.00 | |||||||||
| Italy | 1.40 (0.72, 2.73) | 0.322 | 1.01 (0.48, 2.13) | 0.974 | 0.46 (0.15, 1.43) | 0.180 | 0.83 (0.25, 2.76) | 0.759 | |||||
| Other | 1.05 (0.53, 2.06) | 0.890 | 1.14 (0.55, 2.35) | 0.719 | 0.53 (0.24, 1.12) | 0.068 | 0.94 (0.29, 3.07) | 0.925 | |||||
| At least one relapse during treatment | Yes | 1.61 (1.18, 2.20) | 0.003 | 1.15 (0.86, 1.52) | 0.352 | 1.49 (0.99, 2.24) | 0.057 | 1.24 (0.75, 2.06) | 0.407 | ||||
| No | 1.00 | 1.00 | 1.00 | 1.00 | |||||||||
| MRI - T2 hyperintensive lesions | <9 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| 9+ | 1.06 (0.76, 1.49) | 0.718 | 1.18 (0.87, 1.61) | 0.287 | 0.85 (0.55, 1.31) | 0.461 | 1.52 (0.89, 2.59) | 0.126 | |||||
| MRI - Gadolinium enhancing lesion | At least 1 | 1.16 (0.75, 1.79) | 0.505 | 1.12 (0.81, 1.55) | 0.494 | 1.03 (0.61, 1.75) | 0.898 | 0.59 (0.27, 1.33) | 0.203 | ||||
| Zero | 1.00 | 1.00 | 1.00 | 1.00 | |||||||||
| Not done | 1.13 (0.78, 1.64) | 0.516 | 0.87 (0.57, 1.33) | 0.518 | 0.99 (0.59, 1.66) | 0.962 | 1.17 (0.62, 2.18) | 0.631 | |||||
Abbreviations: CI: Confidence Interval, UHR: Unadjusted Hazard Ratio, IM: intramuscular, SC: subcutaneous, IFN: interferon.
GA: glatiramer acetate.